Chemoembolization for Liver Metastases from Medullary Thyroid Carcinoma

Fromigué, J.; Baère, Thierry De; Baudin, Éric; Dromain, Clarisse; Leboulleux, Sophie; Schlumberger, M.

doi:10.1210/jc.2005-2401

Cited by 108 publications

(78 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the patients with primary liver cancer were often accompanied by liver cirrhosis and portal hypertension. Either stress ulcer or upper gastrointestinal hemorrhage due to esophageal variceal bleeding was induced after TACE treatment [25]. Melena was observed in one case after the treatment, which was diagnosed with severe varicose gastric veins.…”

Section: Discussionmentioning

confidence: 99%

Adverse reaction of a combined treatment for unresectable liver cancer

Ren¹,

Jiang

Peng³

2014

Open Medicine

View full text Add to dashboard Cite

AbstractTo investigate the adverse reactions of transcatheter arterial chemoembolization (TACE) combined with trastuzumab in the treatment of unresectable live cancer, 85 unresectable liver cancer patients were treated with 35 mg epirubicin, with lipiodol and gelatin sponge granule as the embolic agent, and trastuzumab (4mg/kg) was administered intravenously. All the adverse reactions were investigated by blood routine examination and the checking of liver, renal and thyroid functions on the postoperative 2nd and 30th day. No patients died of direct medication. The main adverse reactions included haematological toxicity, liver function lesion and postoperative syndromes such as nausea, vomiting, fever and liver area aching. Two days after the treatment, the amount of the serum total bilirubin (TB) and white blood cell (WBC) increased dramatically, while platelet (PLT) changed a little, and creatinine (Cr) and blood urea nitrogen (BUN) did not change at all. Thirty days after the treatment, blood routine, liver and renal functions were examined, demonstrating that the liver function remained unchanged, PLT decreased apparently, WBC was lower, and Cr and BUN changed slightly compared to those before the treatment. The combined treatment is safe for unresectable liver cancer and thus can be used as a routine intervention method.

show abstract

Section: Discussionmentioning

confidence: 99%

Adverse reaction of a combined treatment for unresectable liver cancer

Ren¹,

Jiang

Peng³

2014

Open Medicine

View full text Add to dashboard Cite

show abstract

“…According to recommendations, treatment should initially include antimotility agents (loperamide or codeine). Further options for unsuccessful cases include the use of somatostatin analogues (193)(194)(195) (B) and the selective resection or arterial chemoembolization of liver metastases to reduce the hypercalcitonemia caused by those lesions (196,197) (B/C).…”

Section: (B/b/d/c)mentioning

confidence: 99%

“…Treatment should be considered for large or progressive lesions, as well as for those associated with the occurrence of diarrhea and/or pain. The available options for treatment include chemoembolization (40-60% achieve partial response/disease stabilization) and tyrosine kinase inhibitor therapy for progressive disease (197,243) (C/D).…”

Section: Liver Metastasesmentioning

confidence: 99%

Diagnóstico, tratamento e seguimento do carcinoma medular de tireoide: recomendações do Departamento de Tireoide da Sociedade Brasileira de Endocrinologia e Metabologia

Maia

Siqueira

Kulcsar

et al. 2014

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Introduction: Medullary thyroid carcinoma (MTC) originates in the thyroid parafollicular cells and represents 3-4% of the malignant neoplasms that affect this gland. Approximately 25% of these cases are hereditary due to activating mutations in the REarranged during Transfection (RET) proto-oncogene. The course of MTC is indolent, and survival rates depend on the tumor stage at diagnosis. The present article describes clinical evidence-based guidelines for the diagnosis, treatment, and follow-up of MTC. Objective: The aim of the consensus described herein, which was elaborated by Brazilian experts and sponsored by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism, was to discuss the diagnosis, treatment, and follow-up of individuals with MTC in accordance with the latest evidence reported in the literature. Materials and methods: After clinical questions were elaborated, the available literature was initially surveyed for evidence in the MedLine-PubMed database, followed by the Embase and Scientific Electronic Library Online/Latin American and Caribbean Health Science Literature (SciELO/Lilacs) databases. The strength of evidence was assessed according to the Oxford classification of evidence levels, which is based on study design, and the best evidence available for each question was selected. Results: Eleven questions corresponded to MTC diagnosis, 8 corresponded to its surgical treatment, and 13 corresponded to follow-up, for a total of 32 recommendations. The present article discusses the clinical and molecular diagnosis, initial surgical treatment, and postoperative management of MTC, as well as the therapeutic options for metastatic disease. Conclusions: MTC should be suspected in individuals who present with thyroid nodules and family histories of MTC, associations with pheochromocytoma and hyperparathyroidism, and/or typical phenotypic characteristics such as ganglioneuromatosis and Marfanoid habitus. Fine-needle nodule aspiration, serum calcitonin measurements, and anatomical-pathological examinations are useful for diagnostic confirmation. Surgery represents the only curative therapeutic strategy. The therapeutic options for metastatic disease remain limited and are restricted to disease control. Judicious postoperative assessments that focus on the identification of residual or recurrent disease are of paramount importance when defining the follow-up and later therapeutic management strategies. Arq Bras Endocrinol Metab. 2014;58(7):667-700

show abstract

“…In patients with metastases predominantly localized in the liver, selective intra-arterial chemoembolization using various drugs has been performed in 23 patients in two studies 23,24 . Some transient partial remission or stabilization (median duration: 24 months), with good symptom palliation, was observed in 70% of cases (16/23).…”

Section: Alternative Treatment Modalitiesmentioning

confidence: 99%